低剂量口服阿帕替尼治疗晚期乳腺癌的临床效果观察(3)
[3] Ginsburg O，Bray F，Coleman M P，et al.The global burden of women’s cancers：a grand challenge in global health[J].Lancet，2017，389(71)：847-860.
[4] Early Breast Cancer Trialists’ Collaborative Group(EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：an overview of the randomised trials[J].Lancet，2005，367(9472)：1687-1717.
[5] Ji G，Hong L，Yang P.Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib：a case report[J].Onco Targets Ther，2016，9(3)：643-647.
[6] Hu X，Zhang J，Xu B，et al.Multicenter phaseⅡ study of apatinib，anovel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer Int[J].Cancer，2014，135(8)：1961-1969.
[7] Hu X，Cao J，Hu W，et al.Multicenter phaseⅡstudy of apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer，2014(14)：820.
[8] Li J，Zhao X，Chen L，et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J].BMC Cancer，2010(10)：529.
[9]廖春梅，劉燕飞.甲磺酸阿帕替尼口服致三阴性乳腺癌患者高血压的预防及护理[J].护理学杂志，2011，26(23)：84-85., 百拇医药(沈伟娟 张溢)
[4] Early Breast Cancer Trialists’ Collaborative Group(EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：an overview of the randomised trials[J].Lancet，2005，367(9472)：1687-1717.
[5] Ji G，Hong L，Yang P.Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib：a case report[J].Onco Targets Ther，2016，9(3)：643-647.
[6] Hu X，Zhang J，Xu B，et al.Multicenter phaseⅡ study of apatinib，anovel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer Int[J].Cancer，2014，135(8)：1961-1969.
[7] Hu X，Cao J，Hu W，et al.Multicenter phaseⅡstudy of apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer，2014(14)：820.
[8] Li J，Zhao X，Chen L，et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J].BMC Cancer，2010(10)：529.
[9]廖春梅，劉燕飞.甲磺酸阿帕替尼口服致三阴性乳腺癌患者高血压的预防及护理[J].护理学杂志，2011，26(23)：84-85., 百拇医药(沈伟娟 张溢)